Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3Alexion Pharma Canada, AstraZeneca Rare Disease

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

Alexion Pharma Canada, Astra...

arrow
CPHI Shenzhen
Not Confirmed

Alexion Pharma Canada, AstraZeneca Rare Di...

Country
arrow
CPHI Shenzhen
Not Confirmed

Ravulizumab

Brand Name : ULTOMIRIS

Patent Number : 2942165

Filing Date : 2015-03-06

Strength per Unit : 10mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2035-03-06

Date Granted : 2022-11-08

blank

02

Alexion Pharma Canada, Astra...

arrow
CPHI Shenzhen
Not Confirmed

Alexion Pharma Canada, AstraZeneca Rare Di...

Country
arrow
CPHI Shenzhen
Not Confirmed

Ravulizumab

Brand Name : ULTOMIRIS

Patent Number : 2942165

Filing Date : 2015-03-06

Strength per Unit : 100 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2035-03-06

Date Granted : 2022-11-08

blank

03

Alexion Pharma Canada, Astra...

arrow
CPHI Shenzhen
Not Confirmed

Alexion Pharma Canada, AstraZeneca Rare Di...

Country
arrow
CPHI Shenzhen
Not Confirmed

Ravulizumab

Brand Name : ULTOMIRIS

Patent Number : 2942165

Filing Date : 2015-03-06

Strength per Unit : 100 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2035-03-06

Date Granted : 2022-11-08

blank